Evaluation of the responsiveness of anti-VEGF treatment in DME
- Conditions
- diabetic retinopathy (DR)
- Registration Number
- NL-OMON29053
- Lead Sponsor
- GSMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
DME patients with completion of 6 intravitreal injections of anti-VEGF at UMCG and at least 1 year follow-up with BCVA
and OCT after start of the treatment will be included.
Exclusion Criteria
high myopia (>6 diopters), glaucoma, media opacities interfering with OCT imaging,
combined retinal disease, intraocular surgery within 12 weeks prior to the first injection,
vitreomacular traction on SD-OCT and those whose SD-OCT images were of poor quality
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method treatment success
- Secondary Outcome Measures
Name Time Method 1 year BCVA and macular thickness